Inhibition of pioglitazone on cardiac hypertrophy in vitro
- VernacularTitle:吡格列酮体外对大鼠心肌肥大的改善作用
- Author:
Shimin WU
;
Ping YE
;
Xin ZHOU
;
Qiong WANG
;
Chenghua LUO
;
Yongxue LIU
;
- Publication Type:Journal Article
- Keywords:
pioglitazone;
cardiac hypertrophy;
ANP;
BNP
- From:
Chinese Pharmacological Bulletin
1987;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
AIM To investigate the effects of pioglitazone on cardiac hypertrophy in vitro. METHODS Hypertrophy in neonatal rat cardiac myocytes (MC) and cardiac nonmyocytes (NMC) was established with angiotensinⅡ (AngⅡ). mRNA expression of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) was measured by reverse transcription polymerase chain reaction (RT PCR). MTT assay and 3H TdR uptake was used to estimate proliferation of NMC. The surface area of MC was analyzed by the aid of NIH Image J software, and the synthetic rate of protein in MC was detected by 3H leucine incorporation. RESULTS In the condition of hypertrophy, increases of surface area,mRNA expression of ANP and BNP and 3H leucine incorporation in MC and an increase of proliferation in NMC were detected, but no changes in mRNA expression of ANP and BNP in NMC. Pioglitazone inhibited the changes above and reduced mRNA expression of ANP and BNP in NMC in a dose dependent manner. CONCLUSION The results demonstrate that pioglitazone inhibits cardiac hypertrophy in vitro and it suggests that pioglitazone has a potential role in the prevention and treatment of cardiac diseases such as cardiac hypertrophy.
